Joseph Lyssikatos Sells 5,000 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) insider Joseph Lyssikatos sold 5,000 shares of the stock in a transaction that occurred on Tuesday, August 19th. The shares were sold at an average price of $19.62, for a total transaction of $98,100.00. Following the transaction, the insider directly owned 947,688 shares of the company’s stock, valued at $18,593,638.56. This represents a 0.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Enliven Therapeutics Stock Up 5.1%

Enliven Therapeutics stock opened at $20.85 on Friday. Enliven Therapeutics, Inc. has a twelve month low of $13.30 and a twelve month high of $30.03. The firm has a 50 day moving average price of $20.61 and a 200-day moving average price of $19.87. The company has a market capitalization of $1.24 billion, a P/E ratio of -10.43 and a beta of 0.93.

Enliven Therapeutics (NASDAQ:ELVN) last released its earnings results on Wednesday, August 13th. The company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.04. Equities analysts expect that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ELVN. Polar Capital Holdings Plc boosted its holdings in Enliven Therapeutics by 267.6% in the 4th quarter. Polar Capital Holdings Plc now owns 2,389,668 shares of the company’s stock valued at $53,768,000 after purchasing an additional 1,739,668 shares during the period. Boxer Capital Management LLC bought a new position in Enliven Therapeutics in the 4th quarter valued at $15,106,000. TCG Crossover Management LLC bought a new position in Enliven Therapeutics in the 2nd quarter valued at $9,990,000. Duquesne Family Office LLC bought a new position in Enliven Therapeutics in the 2nd quarter valued at $9,288,000. Finally, Candriam S.C.A. bought a new position in Enliven Therapeutics in the 2nd quarter valued at $8,358,000. 95.08% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

ELVN has been the subject of a number of research reports. The Goldman Sachs Group initiated coverage on shares of Enliven Therapeutics in a research report on Monday, June 16th. They set a “buy” rating and a $37.00 target price for the company. Robert W. Baird increased their target price on shares of Enliven Therapeutics from $40.00 to $52.00 and gave the company an “outperform” rating in a research report on Monday, June 16th. HC Wainwright raised their price objective on shares of Enliven Therapeutics from $40.00 to $48.00 and gave the stock a “buy” rating in a report on Wednesday, July 2nd. Finally, Jones Trading cut their price objective on shares of Enliven Therapeutics from $36.00 to $27.00 and set a “buy” rating for the company in a report on Friday, May 16th. Five equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Enliven Therapeutics presently has an average rating of “Buy” and an average price target of $41.20.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.